Italian imaging and diagnostics company Bracco, which is affiliated to Merck KGaA of Germany, has entered the North American contrast media market with the establishment of Bracco Diagnostics Canada on July 1.
For the past two years, Bracco's Canadian diagnostics operations have been managed by Bristol-Myers Squibb Canada under the name of Squibb Diagnostics, with the business strengthening in both years. Bracco says that starting immediately, the Bracco name will be phased in on all products. Bracco Diagnostics Canada is located in Toronto.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze